Carcinoma neuroendocrino primario de la glándula mamaria, reporte de caso y revisión de la literatura

Primary neuroendocrine carcinoma of the mammary gland, hormone receptor positive with high histological grade differentiation. Case report and review of the literature

Contenido principal del artículo

Carlos Eduardo Bonilla-González
July Andrea Russi-Noguera

Resumen

El carcinoma neuroendocrino primario de la glándula mamaria pertenece al grupo de tumores neuroendocrinos de la mama. Dada su baja incidencia, la mayor parte de la literatura se basa en series de casos, por lo tanto, su comportamiento biológico y pronóstico muestra resultados divergentes. Su característica principal es el hallazgo histopatológico de la expresión dual en el tumor de marcadores epiteliales y neuroendocrinos en mayor o menor grado que, en algunos casos, inclusive pueden coexistir en la misma célula.  Se presenta el caso de una mujer con diagnóstico de carcinoma neuroendocrino de la mama, con una revisión de la literatura sobre las características clínicas y opciones de manejo.

Detalles del artículo

Biografía del autor/a (VER)

Carlos Eduardo Bonilla-González , Instituto Nacional de Cancerología

MD., Esp. Oncología Clínica

Grupo de Oncología Clínica

July Andrea Russi-Noguera , Centro Javeriano de Oncología Hospital Universitario San Ignacio

MD., Esp: Oncología Clínica

Carolina Gómez, Universidad de La Sabana

MD., Esp. Medicina Interna.

Miller Lasso, Universidad de La Sabana

MD., Esp. Medicina Interna.

Referencias (VER)

Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de Vijver MJ. WHO Classification of Tumours of the Breast, Volume 4. Lyon, France. IARC, No 4. IPress.2012.

Bosotenau M, Bosotenau C, Deacu M, Aschie M. Morphological and immunohistochemical characteristics of a gastric amphicrine tumor: differential diagnosis considerations. Rom J Morphol Embryol. 2011;52(1) Suppl:485-8. PMID: 21424098

Sapino A, Bussolati G. Is detection of endocrine cells in breast adenocarcinoma of diagnostic and clinical significance? Histopathology [Internet].2002;40:211–214. https://doi.org/10.1046/j.1365-2559.2002.01327.x

Miramedi A, Pinder SE, Lee AHS et al. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology [Internet]. 2002;40; 215±222. https://doi.org/10.1046/j.1365-2559.2002.01336.x

Tavassoli FA, Devilee P. Pathology and Genetics: Tumours of the Breast and Female Genital Organs. WHO Classification of Tumours series, 4, 3rd edition. Lyon, France: IARC Press; 2003.

Wang J, Wei B, Albarracín CT, Hu J, Abraham SC, Wu Y. Invasive neuroendocrine carcinoma of the breast: a population based study from the surveillance, epidemiology and end results (SEER) database, BMC Cancer [Internet]. 2014;14: 147. https://doi.org/10.1186/1471-2407-14-147

Angarita FA, Rodríguez JL, Meek E, Sánchez JO, Tawil M, Torregrosa L. Locally-advanced primary neuroendocrine carcinoma of the breast: case report and review of the literature. World J Surg Oncol [Internet].2013;11:128. https://dx.doi.org/10.1186%2F1477-7819-11-128

Gunhan-Bilgen I, Zekioglu O, Ustun EE, Memis A, Erhan Y. Neuroendocrine differentiated breast carcinoma: imaging features correlated with clinical and histopathological findings. Eur Radiol [Internet]. 2003;13:788–793, https://doi.org/10.1007/s00330-002-1567-z

Park YM, Wu Y, Wei W, Yang WT. Primary neuroendocrine carcinoma of the breast: clinical, imaging, and histologic features. AJR Am J Roentgenol [Internet]. 2014; 203: W221–W230,. https://doi.org/10.2214/ajr.13.10749

Righi L, Sapino A, Marchio C, Papotti M, Bussolati G. Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. Semin Diagn Pathol [Internet]. 2010;27:69–76, https://doi.org/10.1053/j.semdp.2009.12.003

Huttner WB, Gerdes HH, Rosa P. The granin (chromogranin/secretogranin) family. Trends Biochem Sci [Internet]. 1991;16(1):27-30. https://doi.org/10.1016/0968-0004(91)90012-k

Silva-Barbosa C, Álzate-Meza M, Messa-Botero O, Chinchilla-Olaya S, Romero-Rojas A. Carcinoma anficrino de glándula mamaria. Reporte de un caso inusual. Rev Colomb Cancerol [Internet]. 2015;19(3):173-179. http://dx.doi.org/10.1016/j.rccan.2015.04.006.

Alkaied H, Harris K, Azab B, Dai Q: Primary neuroendocrine breast cancer, how much do we know so far? Med Oncol [Internet]. 2012; 29:2613–2618. https://doi.org/10.1007/s12032-012-0222-z

[14] Sapino A, Righi L, Cassoni P, Papotti M, Gugliotta P, Bussolati G. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. Mod Patho [Internet]. 2001;14:768–776. https://doi.org/10.1038/modpathol.3880387

Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM. Tumor characteristics and clinical outcome of tubular and mucinous breast carcinomas. J Clin Oncol [Internet]. 1999;17:1442–1448. https://doi.org/10.1200/jco.1999.17.5.1442

Weigelt B, Geyer FC, Horlings HM, Kreike B, Halfwerk H, Reis-Filho JS. Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol [Internet]. 2009;22(11):1401-1414. https://doi.org/10.1038/modpathol.2009.112

Van Krimpen C, Elferink A, Broodman CA, Hop WC, Pronk A, Menke M. The prognostic influence of neuroendocrine differentiation in breast cancer: results of a long-term follow-up study. Breast. [Internet] 2004;13(4):329-33. https://doi.org/10.1016/j.breast.2003.11.008

Wei B, Ding T, Xing Y, Wei W, Tian Z, Tang F, et al. Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer [Internet]. 2010;116(19):4463-73. https://doi.org/10.1002/cncr.25352

Lavigne M, Menet E, Tille JC, Lae M, Fuhrmann, Claire B, et al. Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Modern Pathology [Internet]. 2018;31,68–82. https://doi.org/10.1038/modpathol.2017.107

Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol [Internet]. 2008; 26:3063–3072. https://doi.org/10.1200/jco.2007.15.4377

Inno A, Bogina G, Turazza M, Bortesi L, Duranti S, et. al, Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives. The Oncologist [Internet]. 2016;21:1–5. https://doi.org/10.1634/theoncologist.2015-0309

Yildirim Y, Elagoz S, Koyuncu A, Aydin C, Karadayi K. Management of neuroendocrine carcinomas of the breast: A rare entity. Oncology Letters [Internet]. 2011;2: 887-890. https://dx.doi.org/10.3892%2Fol.2011.320

Buttar A, Mittal K, Khan A, Bathini V. Effective Role of Hormonal Therapy in Metastatic Primary Neuroendocrine Breast Carcinoma. Clin Breast Cancer [Internet]. 2011;11(5):342-5. https://doi.org/10.1016/j.clbc.2011.02.006

Savelli G, Zaniboni A, Bertagna F, Bosio G, Nisa L, et al. Peptide receptor radionuclide therapy (PRRT) in a patient affected by metastatic breast cancer with neuroendocrine differentiation. Breast Care (Basel) [Internet]. 2012;7: 408–410. https://doi.org/10.1159/000343612